NCT04329949: A trial that was reported late by Corcept Therapeutics
This trial has reported, although it was 380 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04329949 |
|---|---|
| Title | A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2020 |
| Completion date | Aug. 23, 2021 |
| Required reporting date | Aug. 23, 2022, midnight |
| Actual reporting date | Sept. 7, 2023 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 380 |